Pilot Study: Echocardiographic and Hemodynamic Effects of Esmolol in Septic Shock Patients

Status

UNKNOWN

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02842983

Enrollment

Registered

2016-07-25

Start date

2014-12-31

Completion date

2016-12-31

Last updated

2016-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Shock, Septic

Keywords

Esmolol, Hypotension, Shock, Septic, Sepsis, Systemic Inflammatory Response Syndrome, Adrenergic beta-1 Receptor Antagonists, Adrenergic Antagonists, Pharmacologic Actions, Physiological Effects of Drugs

Brief summary

After initial hemodynamic stabilization, 36 septic shock patients with heart rate \> of 90 bpm and requiring norepinephrine to maintain mean arterial pressure (MAP) more than 65 mmHg will be randomised into two groups, esmolol group and control group. Patients allocated to esmolol group will receive a continuous esmolol infusion to maintain a lowering of heart rate of 10%. Norepinephrine will be titrated to achieve a MAP more than 65 mmHg. To investigate myocardial performance, the investigators will assess Tissue Doppler imaging by echocardiography and hemodynamic measures. Data will be obtained at baseline ,after esmolol infusion once achieved the predefined heart rate threshold and 72hours after esmolol infusion.

Detailed description

primary outcome were determined according to our previous study of tissue doppler.

Interventions

DRUGEsmolol

conventional management plus esmolol infusion

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* septic shock * fluid optimization * with a cardiac index \> 3 l/min/m2 * Heart Rate \>90 /min

Exclusion criteria

* Cardiogenic shock * Bradycardia * History of Severe Asthma * Indications against Esmolol

Design outcomes

Primary

Measure	Time frame	Description
Echocardiographic assessment of heart function	over a period of 72 hrs	peak systolic velocity measured at the mitral annulus decreased 30% compared with control group

Secondary

Measure	Time frame	Description
Effects on vasopressor requirement	over a period of 72 hrs	Dosage of norepinephrine increased 100% compared with control group
90-day hospital mortality	90 days	—

Countries

China

Contacts

Primary ContactYong-tai Liu, MD

ataiever@163.com+861069155068

Backup ContactLi Weng, MD

wengli@pumch.cn+861069154035

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026